Heterozygous Familial Hypercholesterolemia (HeFH) Latest Advances

Find the Latest Research About Heterozygous Familial Hypercholesterolemia (HeFH)

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 2425 publications

Erratum to "ApoB/LDL-C discordance as a predictor of atherosclerotic cardiovascular disease in genetically confirmed heterozygous familial hypercholesterolemia: A hypothesis-generating cohort study" [J Clin Lipidol 20(3) (2026) 490-503].

Erratum to "ApoB/LDL-C discordance as a predictor of atherosclerotic cardiovascular disease in genetically confirmed heterozygous familial hypercholesterolemia: A hypothesis-generating cohort study" [J Clin Lipidol 20(3) (2026) 490-503].

Journal: Journal of clinical lipidology

Published: May 27, 2026

In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia.

In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia.

Journal: The New England journal of medicine

Published: May 26, 2026

Familial hypercholesterolaemia in children and adolescents: a European Atherosclerosis Society consensus statement.

Familial hypercholesterolaemia in children and adolescents: a European Atherosclerosis Society consensus statement.

Journal: European heart journal

Published: May 25, 2026

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naive Patients.

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naive Patients.

Journal: Circulation

Published: May 15, 2026

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients.

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients.

Journal: Circulation

Published: May 15, 2026

Response to PCSK9 Inhibition Based on LDL Receptor Function in Familial Hypercholesterolemia: A Nonrandomized Clinical Trial.

Response to PCSK9 Inhibition Based on LDL Receptor Function in Familial Hypercholesterolemia: A Nonrandomized Clinical Trial.

Journal: JAMA cardiology

Published: April 29, 2026

Author Correction: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial.

Author Correction: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial.

Journal: Nature medicine

Published: April 17, 2026

Comparison of Clinical Characterization and Therapeutic Strategies between Homozygous Familial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia.

Comparison of Clinical Characterization and Therapeutic Strategies between Homozygous Familial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia.

Journal: Journal of atherosclerosis and thrombosis

Published: March 29, 2026

Real-world lipid outcomes after switching PCSK9-targeting therapies in heterozygous familial hypercholesterolemia: the SHIFT-FH study.

Real-world lipid outcomes after switching PCSK9-targeting therapies in heterozygous familial hypercholesterolemia: the SHIFT-FH study.

Journal: Internal and emergency medicine

Published: March 23, 2026

Genetic dyslipidemias.

Genetic dyslipidemias.

Journal: Annales d'endocrinologie

Published: March 22, 2026

Impact of Genetic Testing Among Patients With Familial Hypercholesterolemia on Adverse Cardiovascular Events　- The Hokuriku-Plus Familial Hypercholesterolemia Registry Study.

Impact of Genetic Testing Among Patients With Familial Hypercholesterolemia on Adverse Cardiovascular Events　- The Hokuriku-Plus Familial Hypercholesterolemia Registry Study.

Journal: Circulation journal : official journal of the Japanese Circulation Society

Published: March 22, 2026

Longitudinal management and novel pharmacological interactions in a patient with HeFH, 21-OHD, and kawasaki disease: a 6-year clinical follow-up.

Longitudinal management and novel pharmacological interactions in a patient with HeFH, 21-OHD, and kawasaki disease: a 6-year clinical follow-up.

Journal: Frontiers in endocrinology

Published: March 05, 2026

Showing 1-12 of 2,425

Last Updated: 06/30/2026